What is Deuterated Drugs?
A deuterated medicine is a small molecule pharmaceutical product in which one or more of the drug's hydrogen atoms have been replaced with the heavier stable isotope deuterium. Deuterated medications are broken down more slowly, linger in the body longer, and hence require less frequent doses. Deuterated pharmaceuticals have much lower rates of metabolism and thus a longer half-life due to the kinetic isotope effect.
The market study is broken down by Type (Austedo, Zepsun and Others) and major geographies with country level break-up.
The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Deuterated Drugs market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Alkeus Pharmaceuticals (United States), Camargo (United States), Celgene (United States), CombiPhos (United States), Concert Pharmaceuticals (United States), DeuteRx (United States), Enanta Pharmaceuticals (United States), Invent Pharmaceuticals (United States), Lundbeck A/S (Denmark) and Neuland Laboratories (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Otsuka Pharmaceuticals (Japan), PharmatrophiX (United States), Protia LLC (United States), Retrotope LLC (United States) and Teva (Israel).
AdvanceMarketAnalytics has segmented the market of Global Deuterated Drugs market by Type, Application and Region.
On the basis of geography, the market of Deuterated Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease, the sub-segment i.e. Huntington’s disease will boost the Deuterated Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
In 2021, Alkeus Launches Clinical Trial for Drug Designed to Reduce Toxins in Retina. The biotech company Alkeus is conducting a multi-center Phase II clinical trial for a drug (ALK-001) that targets the toxic build-up in the retina that is thought to cause degeneration and vision loss. The emerging therapy is a modified form of vitamin A, which when metabolized in the retina, results in much less waste. Scientists developed ALK-001 by replacing hydrogen atoms in vitamin A with deuterium. Known as deuterated vitamin A, it “burns cleaner” than the natural form. Deuterium is a safe, naturally occurring, stable form of hydrogen, which is present in the human body.
- New and Innovative Product are Developing
- Extending Patent Life
- Dosing Frequency & Patient Adherence
- Growing Healthcare Expenditure
- High Cost of Drugs
- Side Effects may cause Persons Death
- Fluctuations in Drugs Supply and Demand Share Due to Enforcement of Stringent Lockdown Measures
Key Target AudienceDeuterated Drug Manufacturers, Deuterated Drug Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
About ApproachTo evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand companys positioning regarding market value, volume and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Frequently Asked Questions (FAQ):
1. What all players are profiled in the study?
The standard version of the report profiles players such as Alkeus Pharmaceuticals (United States), Camargo (United States), Celgene (United States), CombiPhos (United States), Concert Pharmaceuticals (United States), DeuteRx (United States), Enanta Pharmaceuticals (United States), Invent Pharmaceuticals (United States), Lundbeck A/S (Denmark) and Neuland Laboratories (India) etc.
2. Can we have customized study for Deuterated Drugs Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
3. What would be the Market Size of Deuterated Drugs Market by 2027?
Analysts at AMA estimates Deuterated Drugs Market to reach USD Million by 2027.